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Background: Pathogens that are transmitted by ticks to dogs, such as Anaplasma phagocytophilum, Babesia spp.,
Borrelia burgdorferi sensu latu, and Ehrlichia canis, are an increasing problem in the world. One method to prevent
pathogen transmission to dogs is to kill the ticks before transmission occurs. Fluralaner (Bravecto™) is a novel
isoxazoline insecticide and acaricide that provides long persistent antiparasitic activity following systemic
administration. This study investigated the speed of kill of fluralaner against Ixodes ricinus ticks on dogs.
Methods: A total of 48 dogs were randomized to 8 groups of 6 dogs and each dog was infested with 50 female
and 10 male I. ricinus ticks. Two days later (day 0), 4 groups received a single treatment of 25 mg fluralaner/kg body
weight as Bravecto™ chewable tablets; the dogs in the other 4 groups were left untreated. Separate control and
treatment groups were paired at each time point (4, 8, 12, or 24 hours after treatment) for assessment of tick-killing
efficacy. At 4, 8, and 12 weeks after treatment, all dogs were re-infested with 50 female I. ricinus ticks and subsequently
assessed for live or dead ticks at either 4, 8, 12, or 24 hours after re-infestation. Efficacy was calculated for each
assessment time point by comparison of the treatment group with the respective control group.
Results: Tick-killing efficacy was 89.6% at 4 hours, 97.9% at 8 hours, and 100% at 12 and 24 hours after treatment.
Eight hours after re-infestation, efficacy was 96.8%, 83.5%, and 45.8% at 4, 8, and 12 weeks after treatment,
respectively. At least 98.1% tick-killing efficacy was demonstrated 12 and 24 hours after re-infestation over the
entire 12 week study period.
Conclusions: Fluralaner kills ticks rapidly after treatment at 4 hours, and over its entire 12-week period of efficacy,
it achieves an almost complete killing effect within 12 hours after tick infestation. The rapid tick-killing effect
together with the long duration of efficacy enables fluralaner to aid in the prevention of tick borne diseases.
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Ticks are a common nuisance to humans and animals,
as they not only feed on the blood of their host, but also
carry numerous pathogens such as viruses, bacteria, and
parasites. Through feeding, infected ticks can transmit
pathogens to both human and domestic animal hosts,
especially dogs [1,2]. Vector-borne diseases are a grow-
ing problem worldwide [3,4], due to increasing pet own-
ership, more owners traveling with their pets, and the* Correspondence: christina.wengenmayer@msd.de
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article, unless otherwise stated.ability of vector arthropods to establish themselves in
new localities [5]. Ticks and tick-borne diseases are
spreading worldwide and are no longer restricted to cer-
tain areas.
Prevention of tick-borne diseases can be achieved by
avoiding tick habitats and by physical removal of ticks
from infested dogs. A better approach is the use of treat-
ments capable of repelling, or rapidly killing ticks prior to
transmission, ideally with a long duration of efficacy [6-9].
Fluralaner (Bravecto™), a new ectoparasiticide that be-
longs to the novel isoxazoline compound class, is effica-
cious against Ixodes ricinus, Ixodes scapularis, Dermacentor
reticulatus, Dermacentor variabilis, and Rhipicephalus
sanguineus, i.e., against all tick species that potentiallyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tic animals, such as Anaplasma phagocytophilum, Babesia
spp., Borrelia burgdorferi sensu latu, and Ehrlichia canis [3].
Fluralaner’s mode of action is antagonism of ligand-
gated chloride channels (both gamma-aminobutyric acid-
(GABA) receptor and glutamate-receptor) that potently
inhibit the arthropod nervous system [10], resulting in
paralysis and death of fleas and ticks [11]. Fluralaner has
a significantly high selectivity for arthropod versus mam-
malian neurons [10,12] and is well tolerated by dogs that
are at least 8 weeks old, including MDR 1 (−/−) Collies
[13,14].
In dogs, fluralaner has a long elimination half-life, a
long mean residence time, a relatively high apparent vol-
ume of distribution, and a low clearance rate [15]. The
long residence time of fluralaner in the dog’s plasma re-
sults in persistent killing activity on fleas and ticks for
12 weeks after a single oral treatment [16]. The efficacy
of fluralaner depends on ticks attaching to the host’s
skin, commencing feeding and thereby ingesting the ac-
tive compound [11]. Sustained feeding increases risk of
pathogen transmission from ticks to dogs, but transmis-
sion usually does not occur immediately after a tick at-
taches to a dog. Instead, an initial attachment and
feeding period of at least 24 to 48 hours is required be-
fore transmission occurs in most tick-borne disease
systems, a period in which reactivation of tick-borne
pathogens takes place [2]. The time period between at-
tachment and transmission allows a systemic ectoparasi-
ticide such as fluralaner to take effect. If the infected
ticks are killed within this time period, the transmission
can most likely be prevented. Therefore, the speed of
kill, defined as the time necessary to kill already attached
ticks or to kill ticks after re-infestation, is an important
factor in the prevention of tick-borne diseases.
Based on the rationale outlined above, 2 studies were
conducted to evaluate the speed of kill of fluralaner by
measuring the tick-killing efficacy at 4 and 8 hours (study
1) or 12 and 24 hours (study 2) after a single treatment,
and at various time points after re-infestation of these
dogs over the entire 12-week duration of efficacy.
In both studies, I. ricinus ticks were selected to infest
the dogs, because this species is the vector for one of
the most common tick-borne infections, Lyme borrelio-
sis (caused by B. burgdorferi), in the temperate northern
hemisphere [17].
Methods
Both studies were in compliance with German animal
welfare regulations, and ethical approval was obtained
before start of the study by the “Landesuntersuchungsamt
Rheinland-Pfalz”. The studies were conducted in accord-
ance with the OECD Principles of Good Laboratory
Practice (GLP) and the GLP Principles of the GermanChemikaliengesetz (Chemicals Act). Both studies were
conducted as blinded, randomized, negative controlled ef-
ficacy studies.
Study design
The studies investigated the speed of kill of fluralaner
against I. ricinus ticks on dogs. In total, 48 healthy adult
Beagles (≤7 years) that had not been treated with any para-
site control product for at least 12 weeks prior to starting
this study were included. Prior to randomization, dogs
were weighed (range 9.3–19.9 kg) and clinically examined.
Participating dogs were previously infested with 80 fleas
(Ctenocephalides felis) to demonstrate their susceptibility
to parasite infestation and to prove the absence of ecto-
cides. Ranking of the dogs was performed by descending
flea counts (between 63 – 80 fleas/dog) and dogs were
randomly allocated to 8 study groups (4 treatment and 4
corresponding control groups) of 6 dogs each using a
computer generated randomization list.
All dogs were kept indoors. During periods without
parasite infestation, dogs were group-housed within their
corresponding study group, while during periods of
parasite infestations, all dogs were housed individually.
Temperature in the dog housing facility ranged between
17 – 22°C and the relative humidity between 40 – 90%.
Dogs were fed a standard commercially available dry dog
food once daily, and drinking water was provided ad
libitum. General health observations were performed
once daily throughout the study.
Treatment
On day 0 (i.e., day of treatment), dogs in the 4 treatment
groups received fluralaner chewable tablets based on the
dog’s individual body weight to achieve a minimum dose
of 25 mg fluralaner/kg body weight. The fluralaner
chewable tablets were administered by placement in the
back of the oral cavity over the tongue to initiate swal-
lowing. Dogs received half of their daily food ration
within 20 minutes prior to treatment and the balance
immediately thereafter. Each dog was continuously ob-
served for 1 hour after administration to assess whether
chewable tablets were vomited or spit out, which did not
occur. Dogs in the 4 control groups were left untreated.
Tick infestations and assessments
The I. ricinus ticks used in the studies were reared in a
laboratory for at least 2 generations since their introduc-
tion from the wild (Europe). Tick infestations were con-
ducted on medetomidin sedated dogs on days -2, 28
(4 weeks), 56 (8 weeks) and 84 (12 weeks). At each in-
festation time point, every dog was infested with 50 fe-
male unfed adult ticks applied directly to their fur along
the back, lateral side, and head. Approximately 10 male
ticks were additionally applied to give Ixodes females
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held in individual pens until parasite removal. The tick
burden (male and female ticks) of all dogs in each treat-
ment and control group pairing were assessed at either 4
(±0.75), 8 (±0.75), 12 (±1.5), or 24 (±1.5) hours after treat-
ment (week 0) or after re-infestation (weeks 4, 8, and 12).
The entire body of each dog was examined and ticks were
carefully removed using forceps. Ticks were classified as
dead or alive, attached or unattached, and counted.
Personnel conducting tick classification and tick counts
were blinded to the treatment status of each dog.
Statistical analysis
The statistical analysis was performed using the software
package SAS® (SAS Institute Inc., Cary, NC, USA, re-
lease 9.2). The individual animal was the statistical unit
in all statistical calculations. The percentage of tick effi-
cacy was calculated for each treated group and assess-
ment time point according to Abbott’s formula:
Efficacy (%) = 100 x (MC – MT) / MC, where Mc is
the geometric mean of live ticks on control group dogs
and MT is the geometric mean of live ticks on treatment
group dogs. In case of zero counts, the geometric mean








where n is the number of animals, i the index and xi is
the number of ticks on the i-th animal.
Significance of differences was assessed between the
log-counts of the live ticks of each treated group in com-
parison with the log-counts of the respective untreated
control group for each assessment time point. The
treated and control groups were compared using a linear
mixed model that includes treatment group as a fixed ef-
fect and block as a random effect. The two-sided level of
significance for the F-tests of the model effects was set
to α = 0.05.
Results
No treatment-related adverse events were observed in
any of the 24 fluralaner-treated dogs during the 12-week
post-treatment observation period. The mean tick
counts and the detailed efficacy results are shown in
Table 1. Tick-killing efficacy was 89.6% at 4 hours, 97.9%
at 8 hours, and 100% at 12 and 24 hours after treatment.
Eight hours after re-infestation, efficacy was 96.8%,
83.5%, and 45.8% at 4, 8, and 12 weeks after treatment,
respectively. At least 98.1% tick-killing efficacy was dem-
onstrated 12 and 24 hours after re-infestation over the
entire 12 week study period.Tick counts 4, 8, 12 or 24 hours after treatment were
significantly lower (p < 0.0001) in fluralaner treated dogs
compared with tick counts from untreated control dogs.
Tick counts assessed 8, 12 or 24 hours after re-infestation
were also significantly lower (at all time points p < 0.0001;
8 hours following re-infestation in week 12: p < 0.004) in
fluralaner treated dogs compared with untreated control
dogs. Significant lower tick counts were also assessed
4 hours after re-infestation in week 4 (p < 0.03).
Discussion
Fluralaner (Bravecto™) is the first orally administered
ectoparasiticide to exhibit an extended period of efficacy
against ticks. The present study clearly demonstrate that
fluralaner rapidly kills ticks with increasing efficacy over
time, reaching full efficacy at 12 hours for the entire 12-
week duration of efficacy.
The systemic mode of action of fluralaner necessitates
some uptake of the host’s body fluid by the ticks. The
fast killing effect limits this uptake to a short period of
time. The transmission of tick-borne disease pathogens
to the host does not usually occur immediately after tick
attachment, but after sustained feeding.
Pathogens are activated directly in the salivary glands
prior to transmission or require a reactivation period to
replicate and migrate to the salivary glands [2]. This re-
activation period starts upon attachment to the host and
the transmission takes place when the tick regurgitates
excess fluid into the bite wound [2,18].
Several studies have been conducted to assess the time
necessary for pathogen transmission [9,19-21]. Infected
ticks were allowed to feed on host animals for defined
time periods. After removal of the ticks, the host was
checked for the absence or presence of the pathogen, or
a specific immune reaction. If the data indicated that the
host was in contact with the pathogen, the time the tick
was on the host was considered sufficient for pathogen
transmission.
For example, the transmission of B. burgdorferi to mice
by Ixodes nymphs did not occur prior to 24 hours after
attachment: 0 out of 18 mice became infected after expos-
ure to B. burgdorferi-infected I. ricinus nymphs for 24 or
48 hours, and none of 58 mice were infected after expos-
ure to B. burgdorferi-infected I. scapularis nymphs for
24 hours [20,21]. For Babesia canis, transmission from in-
fected D. reticulatus ticks to dogs did not occur prior to
48 hours [19]. Furthermore, Prullage et al., concluded that
the transmission rates of B. burgdorferi, A. phagocytophi-
lum, and B. microti drop significantly if ticks are prevented
from feeding for longer than 24 hours [22].
Once transmission is possible, the probability of pathogen
transmission increases significantly and continues to in-
crease with the duration of the blood meal [21]. Comparing
these transmission times with the results of our study
Table 1 Mean tick counts and tick-killing efficacy (%) after oral administration of fluralaner to dogs
Assessment time pointa 4 hours 8 hours 12 hours 24 hours
Week 0 Mean tick countsb (control/treated) [n] 33.0/3.4 30.6/0.6 28.1/0 15.8/0
Efficacy [%] 89.6# 97.9# 100# 100#
Week 4 Mean tick countsb (control/treated) [n] 36.5/24.4 40.5/1.3 36.7/0.1 30.6/0
Efficacy [%] 33.2* 96.8# 99.7# 100#
Week 8 Mean tick countsb (control/treated) [n] 38.6/31.8 31.2/5.2 32.0/0.3 29.8/0.1
Efficacy [%] 17.5 83.5# 99.2# 99.6#
Week 12 Mean tick countsb (control/treated) [n] 37.4/34.5 30.0/16.2 34.3/0.6 32.7/0.6
Efficacy [%] 7.8 45.8§ 98.3# 98.1#
aAssessment for ticks in hours after treatment or re-infestation.
bGeometric mean.
*Log-counts of live ticks from the treated group were significantly different (p < 0.03) from log-counts of the respective untreated control group.
§Log counts of live ticks from the treated group were significantly different (p < 0.004) from log-counts of the respective untreated control group.
#Log counts of live ticks from the treated group were significantly different (p < 0.0001) from log-counts of the respective untreated control group.
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mission of Borrelia and Babesia pathogens commences.
The A. phagocytophilum and E. canis pathogens are
harbored in the midgut, but can also be found in salivary
glands, which makes an earlier transmission possible.
For example, the transmission of A. phagocytophilum
from I. scapularis nymphs to mice occurs within the first
24 hours [20] and the transmission of E. canis occurs
within 3–6 hours [9]. Thus, the risk of transmission of
such pathogens cannot be completely excluded when
considering the speed of kill of fluralaner and the re-
ported transmission times from laboratory investiga-
tions. However, these studies were conducted under
laboratory conditions; all existing variables of the vector:
host natural state (e.g., vector infection rate and pres-
sure, interrupted tick feeding, variations in the age,
breed, and immune status of the host, and presence of
other reservoir hosts) cannot be replicated in a labora-
tory. More importantly, in several studies conducted in
dogs the use of commercial acaricidal products pro-
tected from an A. phagocytophilum or E. canis infection
[8,23-27]. These products are described as having a
slower speed of kill (i.e., time needed after treatment/
re-infestation to kill >90% of attached ticks) compared
with fluralaner [23,28-31]. Thus, fluralaner is likely to have
at least the same ability to prevent A. phagocytophilum or
E. canis infection in dogs.
The systemic mode of action of fluralaner adds some
more advantages for the user over substances that are
applied topically or by a collar and remain on the surface
of a dog. A decrease of tick efficacy due to the loss of a
collar or by swimming is possible after the use of re-
spective products. Furthermore, the fact that the ticks
are killed after feeding on a fluralaner treated dog also
reduces the possibility of another dog getting infected as
it can happen with solely repellent active substances.
Additionally to its rapid speed of kill and the systemic
mode of action, the long duration of efficacy of fluralanerbenefits owners by permitting fewer treatments over time
than other commercially available monthly acaricidal
products. Frequent and consistent use of ectoparasiticides
is a major tool in tick-borne disease prevention. However,
owner compliance is often poor [32,33], resulting in times
when the dog is not protected [34], i.e. when monthly
treatments are not re-administered in the recommended
treatment interval. This puts not only the dog’s health at
risk, but poses a risk to other dogs and humans, because
an unprotected dog is a potential pathogen reservoir.
Therefore, an ectoparasiticide with a rapid speed of kill and
long duration of efficacy, such as fluralaner (Bravecto™),
helps in the prevention and control of tick-borne diseases.
Conclusions
Fluralaner kills ticks rapidly after treatment at 4 hours,
and over its entire 12-week period of efficacy, it achieves
an almost complete killing effect within 12 hours after
tick infestation. The systemic mode of action of flurala-
ner is of advantage as it thus overcomes the decrease of
efficacy due to the loss of a collar or swimming of the
dog. The 12-week duration of efficacy is an additional
benefit as it overcomes poor owner compliance regard-
ing re-treatment. The rapid tick-killing effect together
with the long duration of efficacy enables fluralaner to
aid in the prevention of tick borne diseases.
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